629 related articles for article (PubMed ID: 27149541)
1. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin for the treatment of irritable bowel syndrome.
Cremonini F; Lembo A
Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066
[TBL] [Abstract][Full Text] [Related]
3. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?
Farrell DJ
J Clin Gastroenterol; 2013 Mar; 47(3):205-11. PubMed ID: 23340064
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.
Laterza L; Ianiro G; Scoleri I; Landi R; Bruno G; Scaldaferri F; Gaetani E; Campanale M; Gasbarrini A
Expert Opin Pharmacother; 2015 Mar; 16(4):607-15. PubMed ID: 25641072
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin: new therapeutic indication and future directions.
Rivkin A; Gim S
Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
[TBL] [Abstract][Full Text] [Related]
8. Microbiome, antibiotics and irritable bowel syndrome.
Ahmad OF; Akbar A
Br Med Bull; 2016 Dec; 120(1):91-99. PubMed ID: 27737852
[TBL] [Abstract][Full Text] [Related]
9. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
10. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.
Pimentel M; Park S; Mirocha J; Kane SV; Kong Y
Ann Intern Med; 2006 Oct; 145(8):557-63. PubMed ID: 17043337
[TBL] [Abstract][Full Text] [Related]
11. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials.
Schoenfeld P; Pimentel M; Chang L; Lembo A; Chey WD; Yu J; Paterson C; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2014 May; 39(10):1161-8. PubMed ID: 24697851
[TBL] [Abstract][Full Text] [Related]
13. The role of rifaximin therapy in patients with irritable bowel syndrome without constipation.
Schey R; Rao SS
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):461-4. PubMed ID: 21780893
[TBL] [Abstract][Full Text] [Related]
14. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Pimentel M
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
[TBL] [Abstract][Full Text] [Related]
15. Role of gut microflora and probiotic effects in the irritable bowel syndrome.
Fanigliulo L; Comparato G; Aragona G; Cavallaro L; Iori V; Maino M; Cavestro GM; Soliani P; Sianesi M; Franzè A; Di Mario F
Acta Biomed; 2006 Aug; 77(2):85-9. PubMed ID: 17172187
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic treatment of constipation-predominant irritable bowel syndrome.
Pimentel M; Chang C; Chua KS; Mirocha J; DiBaise J; Rao S; Amichai M
Dig Dis Sci; 2014 Jun; 59(6):1278-85. PubMed ID: 24788320
[TBL] [Abstract][Full Text] [Related]
18. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
[TBL] [Abstract][Full Text] [Related]
19. Summaries for patients. Can antibiotics improve the symptoms of the irritable bowel syndrome?
Ann Intern Med; 2006 Oct; 145(8):I24. PubMed ID: 17043334
[No Abstract] [Full Text] [Related]
20. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.
Peralta S; Cottone C; Doveri T; Almasio PL; Craxi A
World J Gastroenterol; 2009 Jun; 15(21):2628-31. PubMed ID: 19496193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
